Clinical trials: Orthostatic Hypotension
Neurogenic Orthostatic Hypotension, Autonomic Failure
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
The purpose of this study is to learn more about the effects of abdominal compression and the medication midodrine, two interventions used for the treatment of orthostatic hypotension (low blood pressure on standing), on…
- Conditions
- Neurogenic Orthostatic Hypotension, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy
- Trial name
- NCT04620382
- Testing
- Midodrine, Abdominal compression
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Vanderbilt University Medical Center
Spinal Cord Injury
Transcutaneous Stimulation in Spinal Cord Injury
Cardiovascular disease has become the leading cause of death in the spinal cord injury population. Increased reliance on the renin-angiotensin-aldosterone system (RAAS) is believed to decrease falls in blood pressure when moving…
- Trial name
- SCI (NCT05180227)
- Testing
- DS8R
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- VA Office of Research and Development
Hypotension, Orthostatic, Hypotension
Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury
The goal of this study is to determine the efficacy of the drug Droxidopa (Northera) in increasing blood pressure in subject with hypotension, low blood pressure, which is classified as blood pressure less than 110/70 in males…
- Conditions
- Hypotension, Orthostatic, Hypotension, Spinal Cord Injuries
- Trial name
- NCT03602014
- Testing
- Northera
- Where
- 2 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- James J. Peters Veterans Affairs Medical Center
Orthostatic Hypotension, Spinal Cord Injuries
A Study of Blood Pressure and Blood Supply to the Brain in Persons With a Spinal Cord Injury.
The purpose of this study is to determine how blood pressure and blood flow are controlled during head-up tilt in a semi-upright position.
- Trial name
- NCT00248807
- Testing
- 1.25 mg enalaprilat IV, Head up tilt (HUT)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Spinal Cord Injury
Blood Pressure, Cerebral Blood Flow and Cognition in Spinal Cord Injury
Following spinal cord injury autonomic regulation of the cardiovascular system is impaired, which results in a variety of measurable abnormalities in blood pressure.
- Trial name
- NCT02307565
- Testing
- Midodrine
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- James J. Peters Veterans Affairs Medical Center
Spinal Cord Injury, Autonomic Dysreflexia
Treatment of Post-SCI Hypotension
While treatment strategies for OH have been identified for use in persons with acute SCI, the field of SCI medicine lacks a gold standard for treatment thresholds and well-defined outcome parameters.
- Conditions
- Spinal Cord Injury, Autonomic Dysreflexia, Orthostatic Hypotension, Baroreceptor Integrity
- Trial name
- NCT02919917
- Testing
- Midodrine Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- James J. Peters Veterans Affairs Medical Center
Diabetic Retinopathy, Macular Degeneration
Advancing Understanding of Transportation Options
This Stage II randomized, controlled, longitudinal trial seeks to assess the acceptability, feasibility, and effects of a driving decision aid use among geriatric patients and providers.
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa
- Trial name
- AUTO (NCT04141891)
- Testing
- Driving Decision Aid, Older Drivers Website
- Where
- 3 sites in United States
- Volunteers
- 529 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Arterial Stiffness, Renin Angiotensin Aldosterone System
RAAS and Arterial Stiffness in SCI
The study is examining differences in central arterial stiffness, orthostatic changes in blood pressure, norepinephrine, and plasma renin in individuals with spinal cord injury compared with age-matched uninjured controls.
- Conditions
- Arterial Stiffness, Renin Angiotensin Aldosterone System, Orthostatic Hypotension, Spinal Cord Injury
- Trial name
- NCT04510974
- Testing
- Spinal Cord Injury
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- James J. Peters Veterans Affairs Medical Center
Parkinson Disease, Orthostatic Hypotension
Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease
Levodopa is a precursor of dopamine and is the treatment of choice to treat the motor symptoms of Parkinson's disease (PD); however, the effect of levodopa on cardiovascular autonomic function in PD is poorly understood.
- Trial name
- NCT05487300
- Testing
- Autonomic testing on and off levodopa
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Utah
Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)
Symptomatic NOH in patients with primary autonomic failure is thought to be a consequence of norepinephrine depletion leading to a diminished capacity to effect an appropriate cardiovascular response to an orthostatic challenge…
- Conditions
- Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency, Non-Diabetic Neuropathy, Neurogenic Orthostatic Hypotension
- Trial name
- NOH304 (NCT01132326)
- Testing
- Droxidopa
- Volunteers
- 350 people
- Sponsor
- Chelsea Therapeutics
Neurogenic Orthostatic Hypotension
Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)
Drug therapy for patients suffering from autonomic failure and neurogenic orthostatic hypotension are scarce and not effective. If left untreated, these patients have the highest risk of syncope, falls and fall-related injuries.
- Trial name
- NETAF (NCT02784535)
- Testing
- Atomoxetine
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Vanderbilt University Medical Center
Symptomatic Neurogenic Orthostatic Hypotension
Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
To evaluate the time to treatment intervention in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Non-Diabetic Autonomic Neuropathy (NDAN) or Dopamine Beta Hydroxylase (DBH)…
- Trial name
- RESTORE (NCT02586623)
- Testing
- Droxidopa capsules
- Where
- 168 sites in United States
- Volunteers
- 453 people
- Sponsor
- H. Lundbeck A/S
Parkinson's Disease, Neurogenic Orthostatic Hypotension in Parkinson's Disease
Abdominal Binder to Treat Orthostatic Hypotension (OH) in Parkinson's Disease (PD)
The purpose of the present study is to determine whether the use of an abdominal binder is effective in the non-pharmacological management of orthostatic hypotension in patients suffering from Parkinson's disease
- Trial name
- ABOHP (NCT01971008)
- Testing
- Elastic abdominal binder
- Where
- Austria
- Volunteers
- 15 people
- Sponsor
- Medical University Innsbruck
Symptomatic Neurogenic Orthostatic Hypotension, MSA
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD), Pure Autonomic Failure (PAF)
- Trial name
- REDWOOD (NCT03829657)
- Testing
- ampreloxetine
- Where
- 82 sites in United States, Australia and 17 more
- Volunteers
- 203 people
- Sponsor
- Theravance Biopharma
Symptomatic Neurogenic Orthostatic Hypotension
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3, multi-center, open-label study to evaluate the safety and tolerability of ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic nOH over 182 weeks.
- Trial name
- OAK (NCT04095793)
- Testing
- ampreloxetine
- Where
- 55 sites in United States, Australia and 16 more
- Volunteers
- 110 people
- Sponsor
- Theravance Biopharma
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Chronic Fatigue Syndrome
The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome
Myalgic encephalomyelitis/Chronic fatigue syndrome (ME/CFS), otherwise known as Chronic fatigue syndrome (CFS) or myalgic encephalomyelitis (ME), is an under-recognized disorder whose cause is not yet understood.
- Conditions
- Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Chronic Fatigue Syndrome, Myalgic Encephalomyelitis, Exercise Intolerance
- Trial name
- NCT03674541
- Testing
- Pyridostigmine Bromide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Brigham and Women's Hospital
Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
This multiple-center, 3-part, single-blind dose escalation (Part A), randomized, double-blind (Part B), and open-label multiple dose extension (Part C) study will be conducted in male and female subjects with neurogenic…
- Conditions
- Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease
- Trial name
- NCT02705755
- Testing
- TD-9855
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Theravance Biopharma
Orthostatic Hypotension, Idiopathic Parkinson Disease
Lundbeck TOMs Orthostatic Hypotension
Orthostatic hypotension (OH), which consists in a significant reduction in blood pressure levels upon standing from a seated position, may affect approximately one in three patients with Parkinson's disease (PD).
- Trial name
- NCT04510922
- Testing
- Droxidopa 100 MG [Northera]
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Alberto Espay, MD, MSc
Symptomatic Neurogenic Orthostatic Hypotension
Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3 study to evaluate efficacy, safety, and tolerability of ampreloxetine (TD-9855) in subjects with primary autonomic failures (MSA, PD, or PAF) and symptomatic nOH with up to 4 weeks of treatment.
- Trial name
- SEQUOIA (NCT03750552)
- Testing
- ampreloxetine
- Where
- 125 sites in United States, Australia and 17 more
- Volunteers
- 195 people
- Sponsor
- Theravance Biopharma
Hypertension, Pure Autonomic Failure
Local Heat Stress in Autonomic Failure Patients With Supine Hypertension
Patients with autonomic failure are characterized by disabling orthostatic hypotension (low blood pressure on standing), and at least half of them also have high blood pressure while lying down (supine hypertension).
- Conditions
- Hypertension, Pure Autonomic Failure, Multiple System Atrophy, Autonomic Failure
- Trial name
- NCT02417415
- Testing
- Passive heat stress, Control (non-heating)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Vanderbilt University